We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva Gets Complete Response Letter for Its Neupogen Biosimilar
Teva Gets Complete Response Letter for Its Neupogen Biosimilar
October 8, 2010
Teva has received a complete response letter from the FDA for its BLA for the cancer treatment Neutroval, a biosimilar of Amgen’s Neupogen.